Clinical Trial

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-28; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-06
Trial Details
NCT Number NCT06959537
Lead Sponsor M.D. Anderson Cancer Center
Conditions Breast Cancer
Enrollment 24 participants
Start Date 2025-08-13
Primary Completion 2027-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30